Elisabeth Perzborn

5.6k total citations
70 papers, 4.4k citations indexed

About

Elisabeth Perzborn is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Internal Medicine. According to data from OpenAlex, Elisabeth Perzborn has authored 70 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Cardiology and Cardiovascular Medicine, 29 papers in Hematology and 28 papers in Internal Medicine. Recurrent topics in Elisabeth Perzborn's work include Atrial Fibrillation Management and Outcomes (34 papers), Venous Thromboembolism Diagnosis and Management (28 papers) and Blood Coagulation and Thrombosis Mechanisms (26 papers). Elisabeth Perzborn is often cited by papers focused on Atrial Fibrillation Management and Outcomes (34 papers), Venous Thromboembolism Diagnosis and Management (28 papers) and Blood Coagulation and Thrombosis Mechanisms (26 papers). Elisabeth Perzborn collaborates with scholars based in Germany, United States and France. Elisabeth Perzborn's co-authors include Susanne Roehrig, Alexander Straub, Volker Laux, Dagmar Kubitza, Jens Pohlmann, Stefan Heitmeier, M Samama, Céline Guinet, Frank Misselwitz and Matthias Schramm and has published in prestigious journals such as Nature, Blood and Nature Reviews Drug Discovery.

In The Last Decade

Elisabeth Perzborn

69 papers receiving 4.2k citations

Peers

Countries citing papers authored by Elisabeth Perzborn

Since Specialization

Citations

This map shows the geographic impact of Elisabeth Perzborn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Perzborn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Perzborn more than expected).

Fields of papers citing papers by Elisabeth Perzborn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Perzborn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Perzborn. The network helps show where Elisabeth Perzborn may publish in the future.

Co-authorship network of co-authors of Elisabeth Perzborn

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Perzborn. A scholar is included among the top collaborators of Elisabeth Perzborn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Perzborn. Elisabeth Perzborn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran 2016 ·Thrombosis Research ·Peter Ellinghaus, Elisabeth Perzborn, (unknown), Christoph Gerdes, Stefan Heitmeier, Mayken Visser, Holger Summer, Volker Laux	60
2	Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction 2015 ·Journal of Cardiovascular Pharmacology and Therapeutics ·Elisabeth Perzborn, Stefan Heitmeier, Volker Laux	67
3	Whole blood clots are more resistant to lysis than plasma clots - greater efficacy of rivaroxaban 2013 ·Thrombosis Research ·R. Varin, (unknown), Pezhman Mirshahi, Christophe Klein, (unknown), Jean Chidiac, Elisabeth Perzborn, Massoud Mirshahi, Claudine Soria, Jeannette Soria	73
4	Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis 2012 ·Journal of Thrombosis and Haemostasis ·E. Becker, Elisabeth Perzborn, (unknown), (unknown), (unknown), R. Kast, Juan J. Badimón, Volker Laux	25
5	Anti-Factor Xa chromogenic assay for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicentre field trial 2012 ·M Samama, G. Contant, Theodore E. Spiro, Elisabeth Perzborn, Céline Guinet, Y Gourmelin, Léna Le Flem, Gabriele Rohde, J.L. Martinoli	1
6	Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis 2011 ·Blood Coagulation & Fibrinolysis ·Tom J. Parry, Zhihong Huang, Cailin Chen, Margery A. Connelly, Elisabeth Perzborn, Patricia Andrade‐Gordon, Bruce P. Damiano	11
7	Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls 2011 ·Thrombosis and Haemostasis ·G. Contant, Theodore E. Spiro, Elisabeth Perzborn, Céline Guinet, Y Gourmelin, Léna Le Flem, Gabriele Rohde, J.L. Martinoli, M Samama, (unknown)	201
8	The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor 2010 ·Nature Reviews Drug Discovery ·Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Frank Misselwitz	232
9	Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor 2010 ·Thrombosis and Haemostasis ·(unknown), (unknown), Céline Guinet, Geneviève Plu‐Bureau, François Depasse, Elisabeth Perzborn, M Samama	366
10	Direct inhibitors of coagulation proteins – the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? 2009 ·Thrombosis and Haemostasis ·Elisabeth Perzborn, Stefan Heitmeier, Georges von Degenfeld, (unknown), (unknown), Christoph Gerdes, Frank Misselwitz, Volker Laux	49
11	Preclinical and Clinical Characteristics of Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor 2007 ·Seminars in Thrombosis and Hemostasis ·Volker Laux, Elisabeth Perzborn, Dagmar Kubitza, Frank Misselwitz	58
12	In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor 2005 ·Journal of Thrombosis and Haemostasis ·Elisabeth Perzborn, (unknown), Andreas Wilmen, Jens Pohlmann, Susanne Roehrig, (unknown), Andreas Straub	469
13	NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle 2002 ·British Journal of Pharmacology ·Johannes‐Peter Stasch, Péter Schmidt, Cristina Alonso‐Alija, Heiner Apeler, Klaus Dembowsky, Michael Haerter, (unknown), Torsten Minuth, Elisabeth Perzborn, U. Pleiß, Matthias Schramm, Werner Schroeder, H. Schröder, Elke Stahl, Wolfram Steinke, Frank Wunder	251
14	Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies 2002 ·British Journal of Pharmacology ·Johannes‐Peter Stasch, Cristina Alonso‐Alija, Heiner Apeler, Klaus Dembowsky, Achim Feurer, Torsten Minuth, Elisabeth Perzborn, Matthias Schramm, Alexander Straub	116
15	Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies 2002 ·British Journal of Pharmacology ·Johannes‐Peter Stasch, Klaus Dembowsky, Elisabeth Perzborn, Elke Stahl, Matthias Schramm	106
16	NO-independent regulatory site on soluble guanylate cyclase 2001 ·Nature ·Johannes-Peter Stasch, Eva Maria Becker, Cristina Alonso‐Alija, Heiner Apeler, Klaus Dembowsky, Achim Feurer, R. Gerzer, Torsten Minuth, Elisabeth Perzborn, U. Pleiß, H. Schröder, Werner Schroeder, Elke Stahl, Wolfram Steinke, Alexander Straub, Matthias Schramm	459
17	Binding characteristics of the new thromboxane A2/prostaglandin H2 receptor antagonist [3H]BAY U 3405 to washed human platelets and platelet membranes 1992 ·Biochemical Pharmacology ·Jochen G.W. Theis, (unknown), Elisabeth Perzborn, (unknown)	20
18	pH dependency of the binding of [3H]BAY U 3405 and various non-labelled ligands to the thromboxane A2/prostaglandin H2 receptor of human platelet membranes 1992 ·European Journal of Pharmacology Molecular Pharmacology ·Jochen G.W. Theis, (unknown), Elisabeth Perzborn, (unknown)	2
19	Reduction of in vivo coronary artery thrombosis by the novel thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid. 1989 ·PubMed ·(unknown), Elisabeth Perzborn, (unknown), (unknown), Horst Böshagen	8
20	Nimodipine inhibits carbocyclic thromboxane-induced contractions of cerebral arteries 1981 ·European Journal of Pharmacology ·R. Towart, Elisabeth Perzborn	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact